• Health

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

December 08, 2024 12:30 ET | Source: C4 Therapeutics, Inc. In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest…